|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||3.96 / 18.90|
Oral and Poster Presentations to Highlight Preclinical and Clinical Program Advances for Hypoglycemia and Hypercalcemia
Company extinguishes Hercules term loan; repayment further reduces operating expenses and strengthens XOMA's balance sheet, reflecting its new business strategy
Company outlines new strategic imperatives and value drivers
Congenital Hyperinsulinism Phase 2 study completed and multi-dose study protocol approved in the United Kingdom; Company initiates multi-dose study in hypoglycemic Post-Bariatric Surgery patients
In recent trading, shares of XOMA Corp have crossed above the average analyst 12-month target price of $1.09, changing hands for $6.24/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Company Reached Agreement with MHRA on General Trial Design for Multi-dose Testing in Children 2 Years and Older in the United Kingdom
Novel first-in-class antibody enters clinic for second rare hypoglycemic indication
Data supports continued development of XOMA 129 as a novel targeted therapy for the treatment of hypoglycemic conditions
Trade-Ideas LLC identified XOMA (XOMA) as a weak on high relative volume candidate
Xoma stock is gaining on heavy trading volume early Thursday afternoon after the company reported its 2015 fourth quarter results after yesterday’s closing bell.